Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

about

Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

Item

http://www.wikidata.org/entity/Q42828081

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

@en

Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

@nl

type

Item

label

Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

@en

Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

@nl

prefLabel

Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

@en

Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

@nl

P1476

Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole

@en

P2093

Burge Kabukcu Basay

http://www.w3.org/2001/XMLSchema#string

Zeki Yüncü

http://www.w3.org/2001/XMLSchema#string

Ömer Başay

http://www.w3.org/2001/XMLSchema#string

Önder Öztürk

http://www.w3.org/2001/XMLSchema#string

P2860

A method for estimating the probability of adverse drug reactions

Acute dystonia induced by drug treatment.

Animal models of generalized dystonia.

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Effect of atomoxetine on hyperactivity in an animal model of attention-deficit/hyperactivity disorder (ADHD).

Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years.

Focus on aripiprazole: a review of its use in child and adolescent psychiatry

Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic.

Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist.

P304

221-225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.9758/CPN.2016.14.2.221

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27121436

http://www.w3.org/2001/XMLSchema#string

P932

4857866

http://www.w3.org/2001/XMLSchema#string